跳至主要内容
临床试验/NCT04122222
NCT04122222已完成不适用

Immune Response to Influenza Vaccination in ESRD Patients Undergoing Hemodialysis vs. Hemodiafiltration

Mahidol University0 个研究点目标入组 60 人开始时间: 2016年8月25日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
60
主要终点
measurement antibody titers, determined by hemagglutination inhibition (HI) assay.

研究概览

简要总结

On-line hemodiafiltration (HDF) clears more azotaemic toxins compared to high-flux hemodialysis (HD). The response to vaccination is impaired in dialysis patients. We aimed to study the immune responses to influenza vaccine in dialysis patients treated by HDF vs. HD.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Prevention
盲法
None

盲法说明

Open label

入排标准

性别
All
接受健康志愿者

入选标准

  • ESRD patients aged 18 years or older, who had been treated for more than one month of either thrice weekly on-line hemodiafiltration (HDF) or conventional high flux hemodialysis (HD), with a session dialyzer urea clearance (Kt/V urea) of 1.2 and greater, with a convection volume target of 20 L/session for the HDF group

排除标准

  • Had received any vaccination within the previous four weeks, or influenza vaccination within six months
  • Patient who reported upper respiratory tract symptoms within three days prior to the study vaccination
  • A history of allergy to influenza vaccine or egg
  • Thrombocytopenia
  • In receipt of immunosuppressant medications, chemotherapy, or had immunodeficiency

研究组 & 干预措施

Hemodialysis

Active Comparator

ESRD patients treated by hemodialysis

干预措施: Influenza vaccine (Biological)

Hemodiafiltration

Active Comparator

ESRD patients treated by on-line hemodiafiltration

干预措施: Influenza vaccine (Biological)

结局指标

主要结局

measurement antibody titers, determined by hemagglutination inhibition (HI) assay.

时间窗: 12 months

measurement antibody titers, determined by hemagglutination inhibition (HI) assay.

次要结局

  • measurement T cell subpopulations, determined by flow cytometer AND cell proliferation assay after stimulated with influenza viruses.(12 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Arkom Nongnuch

Assist. Prof

Mahidol University

相似试验

Immune Response to Influenza Vaccine in ESRD Patients | 临床试验